Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04JIM
|
||||
| Former ID |
DIB000176
|
||||
| Drug Name |
UCB-35440
|
||||
| Synonyms |
5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide
|
||||
| Indication | Rhinitis [ICD9: 472.0, 477; ICD10:J00, J30, J31.0] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| CAS Number |
CAS 299460-62-1
|
||||
| Target and Pathway | |||||
| Target(s) | Arachidonate 5-lipoxygenase | Target Info | Modulator | [2] | |
| Histamine H1 receptor | Target Info | Modulator | [2] | ||
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Resolvin D biosynthesis | |||||
| Leukotriene biosynthesis | |||||
| Lipoxin biosynthesis | |||||
| Aspirin triggered resolvin D biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Toxoplasmosishsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| Reactome | Histamine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Arachidonic acid metabolism | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient NetworkWP58:Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of UCB. | ||||
| REF 2 | The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol. 2005 Jan 4;506(3):265-71. Epub 2004 Dec 1. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.